ImmunoBrain Checkpoint

ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company developing novel neuroprotective immunotherapies for neurodegenerative diseases. IBC has developed a proprietary fully human anti-PD-L1 antibody designed based on its mechanism of action for treating Alzheimer's disease and dementia. IBC plans to initiate its first-in-human clinical trial in early 2022.